CD276 and prostate cancer: To avoid over-reliance on melanoma-specific preliminary observations, we integrate mechanistic precedent from other tumor contexts in which B7-H3 expression is shaped by defined signaling and epigenetic programs, including reported AR binding proximal to B7-H3 in prostate cancer and upstream control by stress- and growth-factor pathways.